SCHEDULE 13G/A: Silver Point Capital and Affiliates Disclose 8% Stake in Veradigm Inc.

Silver Point Capital, L.P., along with Edward A. Mule and Robert J. O'Shea, have jointly disclosed a beneficial ownership of 8% in Veradigm Inc.'s common stock, totaling 8,659,500 shares.

Summary

• Silver Point Capital, L.P., a Delaware limited partnership, along with its members Edward A. Mule and Robert J. O'Shea, have filed an Amendment No. 1 to Schedule 13G.
• The filing discloses their beneficial ownership of 8,659,500 shares of Veradigm Inc.'s common stock.
• This aggregate amount represents 8% of Veradigm Inc.'s outstanding common stock.
• The percentage is calculated based on 107,639,978 shares of common stock outstanding as of April 9, 2024, as reported by Veradigm Inc. in its Form 8-K.
• The Reporting Persons (Silver Point Capital, Mr. Mule, and Mr. O'Shea) share both voting and dispositive power over all 8,659,500 shares.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Veradigm Inc., other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by Silver Point Capital in Veradigm Inc., a company operating in the healthcare technology sector. Such disclosures are common for institutional investors accumulating stakes in publicly traded companies, reflecting their investment strategies rather than direct operational or strategic shifts within the industry.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership, potentially influencing market perception and trading activity.

Key Dates

Keywords

Veradigm Inc., Silver Point Capital, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Healthcare Technology